Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment
Protalix said its cash and liquid assets are sufficient to fund operations into late 2027 and reported a year-over-year decrease in Q1 2026 operating expenses. Management also confirmed full enrollment in its pivotal Phase III pegunigalsidase alfa trial.
1. Strong Financial Position
In its Q1 2026 earnings call, Protalix highlighted a strengthened balance sheet with cash and liquid assets projected to cover operating needs through late 2027. The company reduced operating expenses year-over-year, reflecting cost-optimization measures and disciplined spending across R&D and SG&A.
2. Pipeline Advancement
Management confirmed that the Phase III trial of its lead enzyme replacement therapy, pegunigalsidase alfa, has reached full patient enrollment. The company plans to report top-line data in the second half of 2026, aiming to support a Biologics License Application submission thereafter.